Yahoo Finance·2025-11-20 02:42Core Insights - Pfizer has decided to sell its entire remaining stake in BioNTech, indicating a lack of confidence in BioNTech's Covid-19 vaccine and stock performance [1] - BioNTech has been experiencing significant financial losses, with its shares considered expensive despite potential in its drug pipeline [1][5] - The company's prominent drug candidates, BNT327 and BNT323, show potential but have notable weaknesses that may hinder revenue generation [1][6] Financial Performance - BioNTech's Covid-19 vaccine, Comirnaty, peaked at $37.8 billion in sales in 2022, but revenue has since declined significantly, with Q3 2025 revenue at $1.15 billion, a 19% year-over-year decrease [3] - The company reported a net loss of $719.9 million in 2024 and a net loss of $33.55 million in Q3 2025, although the latter was positively impacted by payments from Bristol-Myers Squibb [4] - Analysts project a loss per share of $4.10 in 2025 and $4.04 in 2026, with shares trading at a price-sales ratio of 8.3 times [5] Drug Pipeline - The two main drugs in BioNTech's pipeline are BNT327, an immuno-oncology treatment, and BNT323, a high-precision chemotherapy [6] - BioNTech is set to receive $1.5 billion in upfront payments from Bristol-Myers Squibb, along with potential additional payments totaling $2 billion through 2028, contingent on achieving specific milestones [4]